Mastectomy for Malignancy with CC/MCC DRG Reimbursement

Mastectomy for Malignancy with CC/MCC: Inpatient Reimbursement Overview

DRG 582 encompasses inpatient mastectomy procedures performed for breast malignancy when there is at least one Complication or Comorbidity or Major Complication or Comorbidity present. This Diagnosis-Related Group matters for inpatient reimbursement because it reflects increased resource needs and results in higher Medicare payment relative to uncomplicated mastectomy cases.

Customize your policy alerts

Sign up for drg 582 policy alerts

Get alerted when payer policies referencing 582 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 582 Overview

DRG 582 — Mastectomy for Malignancy with Complication or Comorbidity or Major Complication or Comorbidity covers inpatient admissions for surgical removal of breast tissue for cancer when documented complications or comorbid conditions increase resource use. This Diagnosis-Related Group groups cases with higher clinical complexity than uncomplicated mastectomies and therefore carries higher Medicare reimbursement to account for longer lengths of stay, additional services, and greater resource intensity. Accurate coding of the underlying malignancy, procedure, and any Complication or Comorbidity or Major Complication or Comorbidity is essential for correct Medicare Severity Diagnosis-Related Group assignment and payment.

Clinical Trials

Perioperative surgical technique and reconstruction randomized or comparative studies: trials compare different mastectomy approaches (total/simple mastectomy versus skin-sparing or nipple-sparing techniques) and timing or type of breast reconstruction (immediate versus delayed, implant-based versus autologous reconstruction) in women undergoing mastectomy for breast cancer. These studies enroll patients with operable malignancy who are planned for mastectomy and often stratify by stage, prior radiation, and comorbidities; they assess operative complications, length of stay, readmission, and short-term oncologic margins. Results inform surgeons and hospital administrators about procedure-related morbidity, resource utilization, and pathways that affect inpatient LOS and costs, directly relevant to DRG payment management and quality metrics.
Comparative effectiveness and optimization of perioperative care pathways (enhanced recovery after surgery, analgesia regimens, and thromboprophylaxis) for patients with mastectomy complicated by comorbid conditions: prospective cohort studies and pragmatic randomized trials evaluate multimodal pain control, opioid-sparing strategies, and standardized ERAS protocols specifically in patients with CC/MCC such as diabetes, obesity, or chronic pulmonary disease. These trials focus on reduction of postoperative complications, opioid consumption, inpatient complications (pulmonary, infectious, thrombotic), and discharge disposition among higher-risk surgical oncology patients. Findings are important for payers and providers to reduce complication-driven upcoding, shorten inpatient stays, lower readmissions, and control costs associated with complexity captured in this DRG.
Survivorship and post-discharge outcomes research including rehabilitation, lymphedema prevention, and psychosocial support interventions: longitudinal observational studies and interventional trials examine functional recovery, arm morbidity, lymphedema incidence, return to work, and mental health outcomes after mastectomy in diverse populations including older adults and those requiring adjuvant therapy. These studies often evaluate home-based or clinic-based rehabilitation programs, surveillance strategies for complications, and care coordination models to reduce late complications and downstream utilization. For providers and payers, evidence from these studies guides allocation of post-acute resources, targeted interventions to prevent costly readmissions or chronic disability, and development of care bundles that affect total episode cost for patients assigned to this DRG.

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Perioperative surgical technique and reconstruction randomized or comparative studies: trials compare different mastectomy approaches (total/simple mastectomy versus skin-sparing or nipple-sparing techniques) and timing or type of breast reconstruction (immediate versus delayed, implant-based versus autologous reconstruction) in women undergoing mastectomy for breast cancer. These studies enroll patients with operable malignancy who are planned for mastectomy and often stratify by stage, prior radiation, and comorbidities; they assess operative complications, length of stay, readmission, and short-term oncologic margins. Results inform surgeons and hospital administrators about procedure-related morbidity, resource utilization, and pathways that affect inpatient LOS and costs, directly relevant to DRG payment management and quality metrics.
Comparative effectiveness and optimization of perioperative care pathways (enhanced recovery after surgery, analgesia regimens, and thromboprophylaxis) for patients with mastectomy complicated by comorbid conditions: prospective cohort studies and pragmatic randomized trials evaluate multimodal pain control, opioid-sparing strategies, and standardized ERAS protocols specifically in patients with CC/MCC such as diabetes, obesity, or chronic pulmonary disease. These trials focus on reduction of postoperative complications, opioid consumption, inpatient complications (pulmonary, infectious, thrombotic), and discharge disposition among higher-risk surgical oncology patients. Findings are important for payers and providers to reduce complication-driven upcoding, shorten inpatient stays, lower readmissions, and control costs associated with complexity captured in this DRG.
Survivorship and post-discharge outcomes research including rehabilitation, lymphedema prevention, and psychosocial support interventions: longitudinal observational studies and interventional trials examine functional recovery, arm morbidity, lymphedema incidence, return to work, and mental health outcomes after mastectomy in diverse populations including older adults and those requiring adjuvant therapy. These studies often evaluate home-based or clinic-based rehabilitation programs, surveillance strategies for complications, and care coordination models to reduce late complications and downstream utilization. For providers and payers, evidence from these studies guides allocation of post-acute resources, targeted interventions to prevent costly readmissions or chronic disability, and development of care bundles that affect total episode cost for patients assigned to this DRG.

Mastectomy for Malignancy with CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 582 policy alerts

DRG 582 Overview

Mastectomy for Malignancy with CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 582 policy alerts

DRG 582 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References